Show simple item record

dc.contributor.authorCunniffe, Nick
dc.contributor.authorColes, Alasdair
dc.date.accessioned2021-01-20T16:19:39Z
dc.date.available2021-01-20T16:19:39Z
dc.date.issued2019-06-12
dc.date.submitted2019-04-10
dc.identifier.issn0340-5354
dc.identifier.others00415-019-09421-x
dc.identifier.other9421
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/316501
dc.description.abstractAbstract: The greatest unmet need in multiple sclerosis (MS) are treatments that delay, prevent or reverse progression. One of the most tractable strategies to achieve this is to therapeutically enhance endogenous remyelination; doing so restores nerve conduction and prevents neurodegeneration. The biology of remyelination—centred on the activation, migration, proliferation and differentiation of oligodendrocyte progenitors—has been increasingly clearly defined and druggable targets have now been identified in preclinical work leading to early phase clinical trials. With some phase 2 studies reporting efficacy, the prospect of licensed remyelinating treatments in MS looks increasingly likely. However, there remain many unanswered questions and recent research has revealed a further dimension of complexity to this process that has refined our view of the barriers to remyelination in humans. In this review, we describe the process of remyelination, why this fails in MS, and the latest research that has given new insights into this process. We also discuss the translation of this research into clinical trials, highlighting the treatments that have been tested to date, and the different methods of detecting remyelination in people.
dc.languageen
dc.publisherSpringer Berlin Heidelberg
dc.rightsAttribution 4.0 International (CC BY 4.0)en
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectReview
dc.subjectMultiple sclerosis
dc.subjectRemyelination
dc.subjectClinical trials
dc.subjectVisual evoked potentials
dc.subjectMagnetisation transfer ratio
dc.titlePromoting remyelination in multiple sclerosis
dc.typeArticle
dc.date.updated2021-01-20T16:19:38Z
prism.endingPage44
prism.issueIdentifier1
prism.publicationNameJournal of Neurology
prism.startingPage30
prism.volume268
dc.identifier.doi10.17863/CAM.63609
dcterms.dateAccepted2019-06-05
rioxxterms.versionofrecord10.1007/s00415-019-09421-x
rioxxterms.versionVoR
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidCunniffe, Nick [0000-0002-7562-2838]
dc.identifier.eissn1432-1459


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's licence is described as Attribution 4.0 International (CC BY 4.0)